Anti-Hypertensive Drugs - Baltics

Baltics

Highlights

The Anti-Hypertensive Drugs market in the Baltics is anticipated to achieve a projected revenue of US$18.62m by 2024.
It is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of 0.23%, leading to a market volume of US$18.83m by 2029.
When compared globally, United States is predicted to generate the highest revenue of US$12.29bn in 2024.
The demand for anti-hypertensive drugs in the Baltics is driven by the high prevalence of hypertension in the region.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Anti-Hypertensive Drugs market in Baltics is experiencing steady growth and development.

Customer preferences: Customers in Baltics are becoming increasingly health-conscious and aware of the risks associated with hypertension. As a result, there is a growing demand for effective and affordable anti-hypertensive drugs. Patients in Baltics also prefer medications with minimal side effects and easy-to-use formulations.

Trends in the market: The Anti-Hypertensive Drugs market in Baltics is primarily driven by the increasing prevalence of hypertension in the region. The market is also witnessing a trend towards the development of new and innovative drugs that offer better efficacy and fewer side effects. Additionally, there is a growing preference for combination therapies that provide a more comprehensive approach to hypertension management.

Local special circumstances: Baltics has a relatively small population, which limits the size of the Anti-Hypertensive Drugs market in the region. However, the market is expected to continue growing due to the increasing incidence of hypertension in the region. Additionally, the region has a well-developed healthcare infrastructure, which supports the distribution and uptake of anti-hypertensive drugs.

Underlying macroeconomic factors: The Anti-Hypertensive Drugs market in Baltics is influenced by a range of macroeconomic factors, including government healthcare policies, reimbursement schemes, and the overall economic climate in the region. The region has a relatively low GDP per capita compared to other European countries, which can limit the affordability of anti-hypertensive drugs for some patients. However, the region also has a well-established system of universal healthcare, which ensures that all citizens have access to essential medications, including anti-hypertensive drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.